Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-052877
Filing Date
2025-04-10
Accepted
2025-04-10 16:35:10
Documents
13

Document Format Files

Seq Description Document Type Size
1 DEFA14A evok-20250409.htm   iXBRL DEFA14A 23091
2 GRAPHIC img217104142_0.jpg GRAPHIC 1196440
3 GRAPHIC img217104142_1.jpg GRAPHIC 364670
  Complete submission text file 0000950170-25-052877.txt   3552350

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT evok-20250409.xsd EX-101.SCH 7414
15 EXTRACTED XBRL INSTANCE DOCUMENT evok-20250409_htm.xml XML 1295
Mailing Address 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 230 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

EIN.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-36075 | Film No.: 25828859
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)